EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Roxana Albu

Work experience

Feb 2025-present: Scientific Researcher, Ethical, Legal and Societal Implications | Omics Technologies - Sciensano, Belgium's Public Health Research Organization (Brussels):

- As a Scientific Researcher at Sciensano, I specialize in the ethical and legal dimensions of emerging biomedical technologies, particularly in the use of genomic and health data within European networks.
- My work involves interpreting and implementing complex legal frameworks such as the GDPR, EHDS, and AI Act, while collaborating on EU projects like TEHDAS2, Genome of Europe, and JAPreventNCD.

Jan 2024- Feb 2025: Chief Scientific Officer & Interim Director | Cancer Advocate - Association European Cancer Leagues (ECL) (Brussels):

- Scientific content and expertise for legislative dossiers prioritized by the organization, eg. European Health Data Space, patient involvement in cross-border access to drugs, European Code of Conduct for the Right to Be Forgotten (fair access to financial services for cancer survivors), IARC-WHO European Code Against Cancer version 5, assessment of inequalities in the accessibility of genome-based innovative technologies, interim management of the organization.

Mar 2023 – Jan 2024: EU Project Manager (EHDS) & Training Development Manager | Clinical Research - European Center for Clinical Research Training (ECCRT) (Brussels):

- Managed EU clinical research projects and drove business development
- Led strategic initiatives, stakeholder engagements, and training programs

Jun 2015 – Feb 2023: Health Data Governance, Regulatory Affairs&Data Protection Officer | Clinical Trials - European Organization for Research and Treatment of Cancer (EORTC) (Brussels)

- Acquired expertise in the areas of regulatory affairs, health data protection, European and national regulations for clinical research.
- Oversaw GDPR compliance measures, ensuring adherence to industry standards.
- Served as an International Health Regulations and Compliance Manager for Clinical Trials specializing in regulatory affairs and site activation

Jun 2013 – May 2015: Postdoc Head and Neck Cancer pre-clinical Oncology - University Saint-Luc Hospital (Brussels)

- Tackled the challenge of high failure rates in oncology drug development and the importance of patient-derived tumor xenografts (PDX) as valuable preclinical models due to their ability to maintain key histopathological features and genetic profiles from the original patient tumors.

Sep 2007 – May 2013: PhD Oncology Scientist (Hematological Neoplasms) - Institute de Duve & Ludwig Institute for Cancer Research, Marie Curie Fellow (Brussels)

- Conducted PhD research focused on improving treatment strategies and enhancing the quality of life for patients with blood cancers.

Education and training

2017-2012 : **PhD Pharmaceutical Sciences** | Université Catholique Louvain, Brussels (Marie Curie Fellowship)

2012-2014: **Master of Science (MSc) in Management** (equivalent to MBA) | Field of Economics and Applied Economics | Graduated with Great Distinction

2004-2026 **Master of Science Molecular Biology and Biochemistry** | Romania, Bucharest (Erasmus Padua, Italy)

Additional information

Publications

1. Extracellular domain N-glycosylation controls human thrombopoietin receptor cell surface levels. **Albu RI**, Constantinescu SN.Front Endocrinol (Lausanne). 2011 Nov 11;2:71. doi: 10.3389/fendo.2011.00071. eCollection

2011.PMID: 22649382

2. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, **Albu RI**, Marty C, Gryshkova V, Defour JP, Vertenoeil G, Ngo A, Koay A, Raslova H, Courtoy PJ, Choong ML, Plo I, Vainchenker W, Kralovics R, Constantinescu SN.Blood. 2016 Mar 10;127(10):1325-35. doi: 10.1182/blood-2015-11-681932. Epub 2015 Dec 14.PMID: 26668133

3. An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. Favale F, Messaoudi K, Varghese LN, Boukour S, Pecquet C, Gryshkova V, Defour JP, **Albu RI**, Bluteau O, Ballerini P, Leverger G, Plo I, Debili N, Raslova H, Favier R, Constantinescu SN, Vainchenker W.Blood. 2016 Dec 29;128(26):3146-3158. doi: 10.1182/blood-2016-06-722058. Epub 2016 Nov 10.PMID: 28034873

4. Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. Pecquet C, Chachoua I, Roy A, Balligand T, Vertenoeil G, Leroy E, **Albu RI**, Defour JP, Nivarthi H, Hug E, Xu E, Ould-Amer Y, Mouton C, Colau D, Vertommen D, Shwe MM, Marty C, Plo I, Vainchenker W, Kralovics R, Constantinescu SN.Blood. 2019 Jun 20;133(25):2669-2681. doi: 10.1182/blood-2018-09-874578. Epub 2019 Mar 22.PMID: 30902807

5. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. Medves S, Noël LA, Montano-Almendras CP, **Albu RI**, Schoemans H, Constantinescu SN, Demoulin JB.Haematologica. 2011 Oct;96(10):1406-14. doi: 10.3324/haematol.2011.040147. Epub 2011 Jun 17.PMID: 21685469

6. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. Medves S, Noël LA, Montano-Almendras CP, **Albu RI**, Schoemans H, Constantinescu SN, Demoulin JB.Haematologica. 2011 Oct;96(10):1406-14. doi: 10.3324/haematol.2011.040147. Epub 2011 Jun 17.PMID: 21685469

Projects

1. **External Pool of Experts – European Data Protection Board (EDPB)** Appointed expert contributing to health data regulations, GDPR interpretation, and EHDS-related guidance
2. **Advisor, TEHDAS2 Joint Action (EHDS2 Guidelines)** Co-author of guidelines on opt-out and return of significant findings for secondary use of health data, advisor EHDS2 Guidelines Reuse of Health Data (Citizen Involvement, Data Governance) in TEHDAS2 EU Project
3. **Co-Lead, Ethical, Legal & Societal Implications (ELSI) in Omics Technologies – JANE2 EU Network of Expertise** Leading ELSI work in personalised medicine and cancer omic
4. **Country Expert, External Pool – Genome of Europe initiative:** Contributing national expertise to a landmark pan-European effort to build a high-quality genomic reference for future personalised medicine and public health.
5. **Advisor and contributor to the JARDIN Joint Action (Rare Diseases)**: coordination of stakeholders exchanges and workshops of the JARDIN Joint Action (Rare Diseases), supporting the impact assessment of the European Health Data Space (EHDS) on rare-disease registries and the organisation of care.

Memberships

1. 3 year Marie Currie Fellowship for PhD Studies and exchange of knowledge and expertise
2. Invited contributor to the **European Commission's targeted evaluation of the In Vitro Diagnostics Regulation (IVDR)**.
3. Participation in multiple EU-level workshops and consultations related to EHDS, GDPR, and secondary use of health data (TEHDAS2, EMA, EC consultations).
4. ESMO invited speaker (Cancer Prevention)
5. EUCROF invited speaker xShare (EHDS)
6. Contributor to the **EMA Discussion Paper on Secondary Use of Health Data**, providing expert feedback on GDPR and data reuse for medicines development EMA-_Secondary-use-of-health-data_Discussion-Paper_Stakeholders-consultation.pdf

Other Relevant Information

Beyond my core roles in public health, data governance, and ELSI expertise, I bring over 15 years of multidisciplinary experience spanning oncology research, clinical trials, regulatory affairs, and European-level policy development. My background bridges scientific, ethical, legal, and operational domains, enabling me to translate complex regulatory frameworks into practical guidance for diverse stakeholders. I have contributed to multiple EU-level initiatives, including EHDS, GDPR interpretation for health research, and guidelines for secondary use of health data, while also supporting capacity-building through training, public communication, and stakeholder engagement. My experience across academia, clinical research organisations, public health institutes, and European networks allows me to connect scientific innovation with real-world implementation, always with a focus on trust, transparency, and citizen-centred governance.